Liquid biopsy, the new frontier for cancer diagnosis. Interview with Francesco Gatto
A new technique that makes it possible to study the metabolism of cancer and to understand how it grows, feeds and attempts to invade patients’ bodies. This is the challenge undertaken by Elypta, a Swedish start-up founded by Francesco Gatto, engineer and doctor of research in Systems Biology: to develop new patents in the area of molecular diagnostics with the aim of facilitating the development of more efficient and personalized antitumor therapies.
What advantages does molecular diagnostics offer?